Your search for tofacitinib returned 108 results
Trial Tracker
Combo Tofacitinib Plus Methotrexate vs Adalimumab Plus Methorexate Tx
Fleischmann, R et al. "Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial." DOI: http://dx.doi.org/10.1016/S0140-6736(17)31618-5
News
Tofacitinib Superior to Placebo for Rheumatoid Arthritis
For patients with rheumatoid arthritis, a novel oral Janus kinase inhibitor, tofacitinib, is associated with reduced symptoms when used as monotherapy or in addition to background methotrexate.
News
Tofacitinib Effective for Moderate-to-Severe Ulcerative Colitis
A total of 18.5% patients taking tofacitinib experienced a remission of their condition in 8 weeks compared to just 8.2% of patients receiving placebo.
ACR/ARHP Annual Meeting 2015
Tofacitinib Efficacy Unaffected by Methotrexate Dose in RA
Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and "appeared similar regardless of methotrexate dose" in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
News
Tofacitinib Efficacy Investigated in Patients With Psoriatic Arthritis
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
News
Tofacitinib Benefits Patients With Active Ulcerative Colitis
Tofacitinib, an oral inhibitor of Janus kinase 1, 2, and 3, can reduce disease severity and induce remission better than a placebo in patients with moderately to severely active ulcerative colitis.
Drugs in the Pipeline
Xeljanz Demonstrates Efficacy in Third Phase 3 Ulcerative Colitis Study
Pfizer announced top-line results from OCTAVE Sustain, the third Phase 3 study of Xeljanz (tofacitinib citrate) for the potential treatment of patients with moderately to severely active ulcerative colitis (UC).
